The EPS beat and reaffirmed guidance are positive, but the massive $400M shelf (200% of market cap) and going-concern warning dominate the risk profile. The SENTRY trial's mixed results (met spleen endpoint, missed symptom endpoint) create binary ASCO catalyst risk on June 2. The cash runway into late Q3 2026 forces a near-term capital raise — likely highly dilutive. Traders should watch for the ASCO presentation on June 2 and any pre-announcement of financing terms.
Price Chart
Executive Summary
Karyopharm reported Q1 2026 total revenue of $35.1M (up 17% YoY) and a net loss of $22.4M ($1.02 per basic share), beating consensus EPS of -$1.44 by 29%. The company reaffirmed full-year 2026 revenue guidance of $130M-$150M and completed enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial. However, the Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score), and a $400M shelf registration filed 10 days ago (including a $100M ATM) represents massive potential dilution (~200% of market cap) with a going-concern warning. The cash runway extends only into late Q3 2026, creating acute financing risk.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $35.1M vs $30.0M YoY (+17%); net product revenue $29.2M vs $21.1M YoY (+38%)
- Net loss $22.4M ($1.02 basic share) vs consensus EPS -$1.44 — a 29% beat
- Full-year 2026 guidance reaffirmed: total revenue $130M-$150M, XPOVIO net product revenue $115M-$130M
- Phase 3 SENTRY myelofibrosis trial met SVR35 endpoint but missed Abs-TSS symptom score co-primary endpoint
- Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completed (n=257); topline data expected mid-2026
- Cash $91.2M as of March 31, 2026, including ~$50M from Q1 2026 financing; runway only into late Q3 2026
- $400M universal shelf registration (including $100M ATM) filed May 4, 2026 — ~200% of market cap
- Auditor raised substantial doubt about going concern; massive potential dilution ahead
Financial Impact
Q1 2026 revenue $35.1M (+17% YoY); net loss $22.4M improved from $23.5M YoY; cash burn ~$9M/month; $400M shelf overhang
Risk Factors
- Massive dilution from $400M shelf registration (~200% of market cap) — likely near-term capital raise
- Going-concern warning with cash runway only into late Q3 2026
- SENTRY trial missed symptom endpoint — ASCO presentation on June 2 could disappoint
- XPOVIO demand declining due to new competitive entrants in multiple myeloma
- High debt load ($224M in convertible notes + $120M secured term loan + $72M deferred royalty)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222808 |
| Document: kpti-20260514.htm | 0001193125-26-222808 |
| Document: 0001193125-26-222808-index-headers.html | 0001193125-26-222808 |
| Document: 0001193125-26-222808-index.html | 0001193125-26-222808 |
| Document: 0001193125-26-222808.txt | 0001193125-26-222808 |
| 8-K Data (Synthetic) | 0001193125-26-222808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access